Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Ferric nitrilotriacetate

Ferric nitrilotriacetate

Ferric nitrilotriacetate structure

Ferric nitrilotriacetate 

structure
  • CAS No:

    16448-54-7

  • Formula:

    C6H6FeNO6

  • Chemical Name:

    Ferric nitrilotriacetate

  • Synonyms:

    Iron,[N,N-bis[(carboxy-κO)methyl]glycinato(3-)-κN,κO]-,(T-4)-;Iron,(nitrilotriacetato)-;Iron,[N,N-bis(carboxymethyl)glycinato(3-)-N,O,O′,O′′]-,(T-4)-;Acetic acid,nitrilotri-,iron complex;(T-4)-[N,N-Bis[(carboxy-κO)methyl]glycinato(3-)-κN,κO]iron;Iron nitrilotriacetate;Ferric nitrilotriacetate;Iron-nitrilotriacetic acid chelate;Iron,[nitrilotriacetato(3-)];Fe(III)-NTA complex (1:1);Iron(III) nitrilotriacetate;107288-49-3;5905-54-4;11084-37-0;32696-34-7;174898-25-0

Ferric nitrilotriacetate Basic Attributes

243.96 g/mol

243.954447 g/mol

Z3U5ED15B9

DTXSID60167764

Characteristics

124 Ų

Safety Information

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.|The following wastewater treatment technologies have been investigated for iron (Fe+2): Concentration process: Biological treatment. /Iron (Fe+2)/

SRP: The scientific literature for the use of contact lenses in industry is conflicting. The benefit or detrimental effects of wearing contact lenses depend not only upon the substance, but also on factors including the form of the substance, characteristics and duration of the exposure, the uses of other eye protection equipment, and the hygiene of the lenses. However, there may be individual substances whose irritating or corrosive properties are such that the wearing of contact lenses would be harmful to the eye. In those specific cases, contact lenses should not be worn. In any event, the usual eye protection equipment should be worn even when contact lenses are in place.|All ... /iron/ preparations should be kept in child-proof bottles. /Iron preparations/

Inhalation of ferric salts as dusts and mists is irritating to the respiratory tract. Ferric salts are regarded as skin irritants. /Iron salts/|If inhaled, iron is a local irritant to the lung and gastrointestinal tract. /Iron compounds/

Toxicity

...There is concern that the individual with metabolic defects that impair the ability to regulate iron absorption will be at risk from excessive exposure to iron, primarily as a result of acceleration of accumulation of iron in the body and an earlier onset of clinical symptoms of the disease. /Iron salts/

STUDY OF PHOTOCHEMISTRY OF FERRIC NTA COMPLEXES...UNDERTAKEN & IRRADIATION CHARACTERISTIC OF SUNLIGHT...USED. IN ADDITION TO FORMALDEHYDE, CO2 & IMINODIACETIC ACID (IDA) WERE FORMED... /FERRIC NTA COMPLEXES/

Drug Information

EXPTL USE: Amount exceeding 100 ppm extra dietary iron as ferric nitrilotriacetate produced highly significant increase in survival among chicks infected with Salmonella gallinarum strain 9.|EXPTL USE: Suitable application of iron complexes with nitrilotriacetate should be efficacious in treatment of iron deficiency anemia.

Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)|Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)

Although concentration /NTA/ decrease rapidly with cessation of intake, a small amount was retained in bone after each dose... /Nitrilotriacetic acid/|NTA-(14)C administered orally to rats. 95% was excreted in urine. Less than 1%...as CO2. Absorption of NTA from GI tract varied: dog greater than rat greater than rabbit and monkey. ... Deposited in skeleton. Concentration ... increases with number of doses administered. Most active areas for accumulation are at sites of very active bone formation. /NTA/|After injecting large amount of ferric nitrilotriacetate, complete saturation of transferrins followed. Most excess serum Fe3+-nta existed in association with serum protein rather than as free Fe3+-nta.|In cell, Fe2+ is converted to Fe3+ in ferritin, the latter not being absorbed until cell is physiologically "depleted." In the blood strain, iron could be quickly oxidized by dissolved oxygen to Fe3+, which complexes with specific Fe-transport beta1-globulin.

The mechanism of acute nephrotoxicity of an iron chelate in vivo has been investigated. Administration of a renal carcinogen ferric nitrilotriacetate (Fe-NTA) (15 mg Fe/kg bw, ip) led to selective loss of a renal protein with an apparent molecular mass of 17 kDa. Analysis of the 17 kDa protein by NH2-terminal sequence demonstrated its identity over 16 NH2-terminal residues as a kidney fatty acid-binding protein (k-FABP) that is a proteolytically modified form of alpha 2U-globulin, a major urinary protein of adult male rats. An immunochemical study using anti-alpha 2U-globulin polyclonal antibodies confirmed that a single injection of Fe-NTA led to a decrease in k-FABP levels. However, a 19-kDa protein identical to the alpha 2U-globulin progressively appeared in the kidney, suggesting that the proteolytic processing of alpha 2U-globulin in the renal proximal tubules was suppressed by the treatment with Fe-NTA. By monitoring k-FABP and its precursor alpha 2U-globulin, it was determined that repeated exposure to Fe-NTA caused suppression of both proteolytic and endocytotic activity of the kidney.

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for shock and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool. /Iron and related compounds/|Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious. Monitor cardiac rhythm and treat arrhythmias if necessary ... . Start an IV with lactated Ringer's /SRP: "To keep open", minimal flow rate/. Watch for signs of fluid overload. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Iron and related compounds/|Maintain an open airway and assist ventilation if necessary. Treat shock caused by hemorrhagic gastrointestinitis aggressively with intravenous crystalloid fluids, and replace blood if needed. Patients are often markedly hypovolemic owing to gastrointestinal losses and third spacing of fluids into the intestinal wall and interstitial space. Treat coma, seizures, and metabolic acidosis if they occur. For seriously intoxicated victims (eg, shock, severe acidosis, and/or serum iron > 500-600 mcg/dL) administer deferoxamine. Monitor the urine for the urine for the characteristic orange or pink deferoxamine-iron complex. Therapy may be stopped when the urine returns to normal or when the serum iron level decreases to the normal range. Prolonged deferoxamine has been associated with adult respiratory distress syndrome and Yersinia sepsis.|Activated charcoal is not effective. Ipecac is not recommended, because it can aggravate iron-induced gastrointestinal irritation and interfere with whole bowel irrigation. Consider gastric lavage if product was a liquid formulation or tablets were chewed. Do-not use phosphate-containing solutions for lavage; these may result in life-threatening hypernatremia, hyperphosphatemia, and hypocalcemia. Bicarbonate and deferoxamine lavage are of doubtful efficacy. Deferoxamine lavage is not effective and may enhance iron absorption. Whole-bowel irrigation is very effective for ingested tablets and may be considered first-line treatment, especially if large numbers of tablets are visible on plain abdominal x-ray. Massive ingestions may lead to concretions or bezoars. Repeated or prolonged whole-bowel irrigation may remove tablets. Endoscopy or surgical gastrotomy is rarely required.|Hemodialysis and hemoperfusion are not effective for removing iron but may be necessary to remove iron-deferoxamine complex in patients with renal failure. Exchange transfusion is occasionally used for massive pediatric ingestions but is of questionable efficacy.

FE(III)-NTA

Ferric nitrilotriacetate Use and Manufacturing

MEDICATION

Computed Properties

Molecular Weight:243.96
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:3
Exact Mass:243.954447
Monoisotopic Mass:243.954447
Topological Polar Surface Area:124
Heavy Atom Count:14
Complexity:171
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.